Longitudinal Tumor Size and Neutrophil‐to‐Lymphocyte Ratio Are Prognostic Biomarkers for Overall Survival in Patients With Advanced Non‐Small Cell Lung Cancer Treated With Durvalumab-Reference-Cited by-同舟云学术

Longitudinal Tumor Size and Neutrophil‐to‐Lymphocyte Ratio Are Prognostic Biomarkers for Overall Survival in Patients With Advanced Non‐Small Cell Lung Cancer Treated With Durvalumab

Published:2020-12-21 Issue:1 Volume:10 Page:67-74
ISSN:2163-8306
Container-title:CPT: Pharmacometrics & Systems Pharmacology
language:en
Short-container-title:CPT Pharmacometrics Syst. Pharmacol.

Author:

Gavrilov Sergey¹²,Zhudenkov Kirill¹,Helmlinger Gabriel¹³,Dunyak James³,Peskov Kirill¹⁴,Aksenov Sergey³

Affiliation:

1. M&S Decisions LLC Moscow Russia

2. Faculty CMC of Lomonosov MSU Moscow Russia

3. Clinical Pharmacology and Quantitative Pharmacology Clinical Pharmacology & Safety Sciences BioPharmaceuticals R&D AstraZeneca Boston Massachusetts USA

4. Computational Oncology Group I.M. Sechenov First Moscow State Medical University Moscow Russia

Funder

AstraZeneca

Publisher

Wiley

Subject

Pharmacology (medical),Modeling and Simulation

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/psp4.12578

Reference50 articles.

1. Cancer statistics, 2019

2. Current Molecular-Targeted Therapies in NSCLC and Their Mechanism of Resistance